

Durata Therapeutics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 09-Jul-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Subsidiary Companies..... 7

Product Portfolio Summary..... 8

Product Portfolio Financials..... 11

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

Durata Therapeutics Inc

COMPANY OVERVIEW

Company Name	Durata Therapeutics Inc
Parent Company Name	Durata Therapeutics Inc
Website	http://www.duratatherapeutics.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	13
Number of Patents as Owner	24
Number of Patents as Third Party	2
Number of Deals	11
Key Indications	Bacterial infection,Bacterial skin infection,Gram positive bacterium infection,MRSA infection,Streptococcus pneumoniae infection
Key Target-based Actions	Peptide deformylase inhibitor,N-acetylglucosamine deacetylase inhibitor,Unspecified enzyme inhibitor,Chondroitin sulfate synthase stimulator
Key Technologies	Small molecule therapeutic,Antibiotic,Oral formulation,Biological therapeutic,Dermatological formulation,Injectable formulation,Parenteral formulation unspecified,Peptide,Cell culture technique,Isolation technology

COMPANY PROFILE

SUMMARY

Durata Therapeutics Inc, a biopharmaceutical company, was formed in 2009 by a 5-member venture capital syndicate for the development of antibiotic programs to treat infectious diseases.

LOCATION

In November 2012, the company planned to relocate its corporate headquarters from Morristown, NJ, to Chicago, IL.

ACQUISITIONS & SPIN-OFFS

In December 2009, Durata acquired Vicuron Pharmaceuticals from Pfizer. The transaction was funded through a stock purchase by New Leaf Venture Partners, Domain Associates, Aisling Capital, Sofinnova Ventures and Canaan Partners. Durata obtained rights to dalbavancin and two undisclosed preclinical antibiotic programs.

FINANCIAL

In April 2013, Durata raised net proceeds of \$54.1 million in an equity offering.

In April 2013, the company planned to raise the net proceeds of \$46.3 million through an underwritten public offering of 7.15 million shares of its common stock at \$7 each. The underwriters were granted 30-day option to purchase additional shares up to 1,072,500 and the offering was expected to close on or about April 17, 2013; later that month, the public offering of 8,222,500 shares of common stock was closed.

In March 2013, the company entered into a US \$20 million debt facility with Oxford Finance LLC; at that time, net proceeds were expected to be received by the end of that month.

In March 2012, Durata planned to conduct an IPO; in July 2012, the company priced 7.5 million shares of common stock at \$9 each. The underwriters were granted 30-day option to purchase additional shares up to 1.125 million and the offering was expected to close on July 24, 2012. The company also reported that the shares would be traded on NASDAQ under the ticker symbol 'DRTX'; later that month, the IPO of 8.625 million common stock shares was closed before the underwriting discounts. By that time, a registration statement relating to these securities had been declared effective by the SEC; by September 2012, net proceeds of \$73.9 million (approximately \$71.4 million after the payment of \$2.5 million of other offering expenses payable by the company) had been raised from the offering.

[Return to Table of Contents](#)



SUBSIDIARY COMPANIES


Names
Vicuron Pharmaceuticals Inc

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	3	11	14
Dermatological disease	1	2	3
Respiratory disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	2
Discontinued	2
No Development Reported	7

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Drug - Asset Divestment	1	0	0	0	1
Drug - Early Research/Development	1	0	1	0	2
Drug - Development/Commercialization License	1	0	2	0	4
Drug - Manufacturing/Supply	0	0	3	0	3

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	0	23
Dermatological disease	0	9

Trials by Phase

Phase	Ongoing	All
Phase 3	0	7
Phase 2	0	7
Phase 1	0	5
Phase not specified	0	10

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Gastrointestinal disease	4	1	5
Degeneration	1	0	1
Immune disorder	0	1	1
Musculoskeletal disease	1	0	1
Genetic disorder	1	0	1
Metabolic disorder	1	0	1
Neurological disease	1	0	1
Respiratory disease	5	1	6
Infectious disease	26	2	28
Inflammatory disease	2	0	2

[Return to Table of Contents](#)




Dermatological disease	4	0	4
------------------------	---	---	---


* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2014



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

dalbavancin

Drug Name	dalbavancin
Key Synonyms	dalbavancin, Exulett, Zeven
Originator Company	Biosearch Italia SpA
Active Companies	Durata Therapeutics Inc
Inactive Companies	RaQualia Pharma Inc, Pfizer Inc, Vicuron Pharmaceuticals Inc, Biosearch Italia SpA
Highest Status	Phase 3 Clinical
Active Indications	Streptococcus pneumoniae infection, MRSA infection, Bacterial skin infection, Gram positive bacterium infection
Target-based Actions	
Other Actions	Antibacterial, Systemic dermatological antibacterial product, Bacterial cell wall synthesis inhibitor
Technologies	Intravenous formulation, Antibiotic, Glycoprotein, Infusion, Small molecule therapeutic
Last Change Date	21-May-2013

lincosamide antibacterials, Durata

Drug Name	lincosamide antibacterials, Durata
Key Synonyms	
Originator Company	Vicuron Pharmaceuticals Inc
Active Companies	Durata Therapeutics Inc
Inactive Companies	Vicuron Pharmaceuticals Inc
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Ribosome binding agent, Bacterial protein synthesis inhibitor
Technologies	Antibiotic, Small molecule therapeutic
Last Change Date	21-Mar-2013

[Return to Table of Contents](#)



pleuromutilins (bacterial infections), Durata

Drug Name	pleuromutilins (bacterial infections), Durata
Key Synonyms	
Originator Company	Durata Therapeutics Inc
Active Companies	Durata Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Antibacterial, Protein synthesis inhibitor
Technologies	Antibiotic, Small molecule therapeutic
Last Change Date	21-Mar-2013

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

